Through a seamlessly integrated workflow, the assay allows clinician-researchers to:
- Distinguish true MRD from pre-leukemic or precursor clones with a limit of detection of 0.01%,
- Reveal clonal architecture (co-occurrence and zygosity of mutation) and uncover the order of acquisition of mutations (phylogeny),
- Track clonal dynamics and immunophenotypic drifts through disease course to identify therapeutic targets and therapy-resistance subclones.
- Generate analysis ready reports for single as well as time course analysis using the new MRD AML software.
- Multiplex up to three samples based on different genotype profiles, the pipeline will demultiplex and produce the MRD reports for each.